Anemia drugs may face tougher restrictions in the U.S.

The FDA's cancer-drugs advisory panel is scheduled to meet Thursday to consider regulatory action on the use of Johnson & Johnson's and Amgen's anemia drugs, which have been linked in certain cancer patients to faster tumor development, shortened survival and higher blood-clot risk. The agency is considering nullifying the approval of the drugs -- marketed as Procrit by J&J and Epogen and Aranesp by Amgen -- for use in cancer patients.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA